These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 24629000)
1. The antibacterial effect of nitric oxide against ESBL-producing uropathogenic E. coli is improved by combination with miconazole and polymyxin B nonapeptide. Bang CS; Kinnunen A; Karlsson M; Önnberg A; Söderquist B; Persson K BMC Microbiol; 2014 Mar; 14():65. PubMed ID: 24629000 [TBL] [Abstract][Full Text] [Related]
2. Role of flavohemoglobin in combating nitrosative stress in uropathogenic Escherichia coli--implications for urinary tract infection. Svensson L; Poljakovic M; Säve S; Gilberthorpe N; Schön T; Strid S; Corker H; Poole RK; Persson K Microb Pathog; 2010 Sep; 49(3):59-66. PubMed ID: 20399845 [TBL] [Abstract][Full Text] [Related]
3. Ceftibuten-induced filamentation of extended spectrum beta lactamase (ESBL)-producing uropathogenic Escherichia coli alters host cell responses during an in vitro infection. Demirel I; Kruse R; Önnberg A; Persson K Microb Pathog; 2015 Jan; 78():52-62. PubMed ID: 25433242 [TBL] [Abstract][Full Text] [Related]
4. Uropathogenic Escherichia coli and tolerance to nitric oxide: the role of flavohemoglobin. Svensson L; Marklund BI; Poljakovic M; Persson K J Urol; 2006 Feb; 175(2):749-53. PubMed ID: 16407044 [TBL] [Abstract][Full Text] [Related]
5. Carbon monoxide-releasing molecule-3 (CORM-3; Ru(CO)3Cl(glycinate)) as a tool to study the concerted effects of carbon monoxide and nitric oxide on bacterial flavohemoglobin Hmp: applications and pitfalls. Tinajero-Trejo M; Denby KJ; Sedelnikova SE; Hassoubah SA; Mann BE; Poole RK J Biol Chem; 2014 Oct; 289(43):29471-82. PubMed ID: 25193663 [TBL] [Abstract][Full Text] [Related]
6. The hmp gene encoding the NO-inducible flavohaemoglobin in Escherichia coli confers a protective advantage in resisting killing within macrophages, but not in vitro: links with swarming motility. Stevanin TM; Read RC; Poole RK Gene; 2007 Aug; 398(1-2):62-8. PubMed ID: 17611046 [TBL] [Abstract][Full Text] [Related]
7. The cytochrome bd-I respiratory oxidase augments survival of multidrug-resistant Escherichia coli during infection. Shepherd M; Achard ME; Idris A; Totsika M; Phan MD; Peters KM; Sarkar S; Ribeiro CA; Holyoake LV; Ladakis D; Ulett GC; Sweet MJ; Poole RK; McEwan AG; Schembri MA Sci Rep; 2016 Oct; 6():35285. PubMed ID: 27767067 [TBL] [Abstract][Full Text] [Related]
8. Multiresistant uropathogenic extended-spectrum β-lactamase (ESBL)-producing Escherichia coli are susceptible to the carbon monoxide releasing molecule-2 (CORM-2). Bang CS; Kruse R; Demirel I; Onnberg A; Söderquist B; Persson K Microb Pathog; 2014 Jan; 66():29-35. PubMed ID: 24361394 [TBL] [Abstract][Full Text] [Related]
9. Cell death and biomass reduction in biofilms of multidrug resistant extended spectrum β-lactamase-producing uropathogenic Escherichia coli isolates by 1,8-cineole. Vazquez NM; Mariani F; Torres PS; Moreno S; Galván EM PLoS One; 2020; 15(11):e0241978. PubMed ID: 33152054 [TBL] [Abstract][Full Text] [Related]
10. Nitric oxide formation by Escherichia coli. Dependence on nitrite reductase, the NO-sensing regulator Fnr, and flavohemoglobin Hmp. Corker H; Poole RK J Biol Chem; 2003 Aug; 278(34):31584-92. PubMed ID: 12783887 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and Antibiotic Susceptibility Patterns of Extended-Spectrum ß-Lactamase and Metallo-ß-Lactamase-Producing Uropathogenic Escherichia coli Isolates. Ghadiri H; Vaez H; Razavi-Azarkhiavi K; Rezaee R; Haji-Noormohammadi M; Rahimi AA; Vaez V; Kalantar E Lab Med; 2014; 45(4):291-6. PubMed ID: 25316659 [TBL] [Abstract][Full Text] [Related]
12. Flavohemoglobin Hmp affords inducible protection for Escherichia coli respiration, catalyzed by cytochromes bo' or bd, from nitric oxide. Stevanin TM; Ioannidis N; Mills CE; Kim SO; Hughes MN; Poole RK J Biol Chem; 2000 Nov; 275(46):35868-75. PubMed ID: 10915782 [TBL] [Abstract][Full Text] [Related]
13. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations]. Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650 [TBL] [Abstract][Full Text] [Related]
14. Is transmission electron microscopy (TEM) a promising approach for qualitative and quantitative investigations of polymyxin B and miconazole interactions with cellular and subcellular structures of Staphylococcus pseudintermedius, Escherichia coli, Pseudomonas aeruginosa and Malassezia pachydermatis? Voget M; Lorenz D; Lieber-Tenorio E; Hauck R; Meyer M; Cieslicki M Vet Microbiol; 2015 Dec; 181(3-4):261-70. PubMed ID: 26527257 [TBL] [Abstract][Full Text] [Related]
15. Synergism of the antimicrobial agents miconazole, bacitracin and polymyxin B. Cornelissen F; Van den Bossche H Chemotherapy; 1983; 29(6):419-27. PubMed ID: 6317296 [TBL] [Abstract][Full Text] [Related]
17. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Azap OK; Arslan H; Serefhanoğlu K; Colakoğlu S; Erdoğan H; Timurkaynak F; Senger SS Clin Microbiol Infect; 2010 Feb; 16(2):147-51. PubMed ID: 19689464 [TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of miconazole and polymyxin B on microbial pathogens. Pietschmann S; Hoffmann K; Voget M; Pison U Vet Res Commun; 2009 Aug; 33(6):489-505. PubMed ID: 19085068 [TBL] [Abstract][Full Text] [Related]
19. Clonal Relatedness, Phylotyping and Antimicrobial Susceptibility of Extended- spectrum-beta-lactamase Producing Uropathogenic Escherichia coli Isolates from Outpatients and Inpatients. Azimzadeh N; Derakhshandeh A; Motamedifar M; Naziri Z Infect Disord Drug Targets; 2020; 20(5):659-666. PubMed ID: 31322075 [TBL] [Abstract][Full Text] [Related]